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ARTICLE 
Abstract. Two cases of treatment site granulomatous reac- 
tion to Zyderm Collagen Implant that occurred in spite o f  
a negative skin test are reported. A delayed hypersensitiv- 
ity reaction to ZCI is suggested by the clinical time course 
and the histologic findings of hypersensitivity granulomas. 
Humoral immunity is also implicated in the reaction since 
elevated anti-Zyderm serum antibodies and plasma cell in- 
filtrates are present. Resolution of the clinical signs and 
symptoms occurred over several months with no treat- 
ment. The physician using ZCI should be aware of this rare 
adverse reaction. 
Injectable collagen implant (Zyderm) has been pro- 
moted for the correction of soft-tissue contour de- 
fects. Scars amenable to treatment include certain de- 
pressed acne scars, age lines, rhytids, viral pox scars, 
traumatic scars, iatrogenic scars, and certain post- 
surgical scars. Zyderm Collagen Implant (ZCI) is pu- 
rified bovine dermal collagen which has undergone 
selective proteolytic hydrolysis of its telopeptide por- 
tions to decrease its immunogenicity. It is suspended 
in a physiological saline buffer containing 0.3% lido- 
caine for injection. After intradermal injection, the 
substance becomes incorporated into the host's der- 
mal collagen matrix. Patients are given a skin test 
with ZCI before therapeutic use to detect potential 
sensitivity to the implant. A positive reaction has 
been reported in about 3% of patients.' Histologi- 
cally, positive skin tests show a foreign-body-like 
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granuloma. In the presence of a negative skin test, 
adverse reactions in treatment sites have not been 
reported. This paper presents two patients with such 
reactions and defines their clinical course. 
CASE REPORTS 
Case 1 
A 36-year-old white woman presented for treat- 
ment of severe acne scarring. After discussion of 
treatment options, ZCI followed by dermabrasion 
was chosen. A 0.1-cc test dose was implanted in the 
right forearm in the usual fashion. The patient had no 
reaction at 48 hours and at 1 month the test site was 
clinically and histologically negative. Two cc of Zy- 
derm were implanted in three areas of the right 
cheek. Eighteen days postinjection, the patient devel- 
oped persistent swelling and firmness in the area. 
She presented, 21 days postinjection, with induration 
and an urticaria1 violaceous plaque at the injection 
site as well as with right periorbital edema. The test 
injection site on her forearm remained negative. She 
denied systemic symptoms. Prednisone, 40 mglday 
for 3 days, was given for the periorbital edema which 
then rapidly subsided. The indurated and violaceous 
nodular lesions at the injection sites persisted (Fig. 1). 
Because of the patient's history of chronic sinus infec- 
tions and the reported sinus problems concurrent 
with ZCI allergy, she was begun on cephadroxil 500 
mg daily. This had no effect on the reaction. A biopsy 
specimen taken from the involved site showed a 
granulomatous reaction. The serum showed the pres- 
ence of anti-Zyderm antibodies as measured by the 
Collagen Corporation, but the patient's antinuclear 
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FIGURE 1. Treatment site reactions consisting of erythema- 
tous, indurated nodules at  sites of injection with Zyderm 
Collagen Implant. 
antibody assay, erythrocyte sedimentation rate, and 
complete blood count were normal. 
The induration and discoloration at the treatment 
sites on her face gradually resolved over the next 6 
months (Fig. 2). During this period, she did occasion- 
ally experience a flare-up on her face as well as on the 
test dose site, manifested by induration and tender- 
ness. This often followed sun exposure. 
Case 2 
A 42-year-old healthy white woman presented for 
treatment of two traumatic scars on the left cheek. 
She had no contraindications to ZCI therapy, and her 
scars appeared amenable to this therapy. A standard 
0.1 cc test dose of ZCI was implanted in the right 
forearm. There were no adverse reactions at 48 hours 
or at  1 month. Clinically her test dose was negative, 
and treatment was initiated with 0.4 cc of ZCI in the 
left cheek. An immediate 130% correction was 
achieved, and there was no complication at the time 
of injection. During the next 2 months, she experi- 
enced intermittent redness and induration at the in- 
jection site. The test site on her arm remained nega- 
tive. She denied any systemic symptoms. A biopsy 
specimen from the left cheek site showed a granu- 
lomatous inflammatory reaction. Serum drawn at this 
time revealed the presence of anti-Zyderm antibod- 
ies, but the antinuclear antibody assay and the eryth- 
rocyte sedimentation rate were normal. Observation 
of the lesion over the next several months showed a 
gradual and complete clinical remission without 
treatment. 
FIGURE 2. Healing of reaction sites at  6 months without 
treatment. 
acid-Schiff (PAS), Movat’s pentachrome, and alcian 
blue (at pH 0.4 and 2.5) stains were also used. 
Similar changes were noted in both specimens. 
The epidermis was unremarkable. Solar elastosis in 
the papillary and upper reticular dermis was noted. 
The reticular dermis was extensively altered by a 
complex admixture of granulomatous inflammation 
and scar tissue (Fig. 3 ) .  These changes expanded the 
reticular dermis and extended into the subcutis. The 
cellular constituents of the granulomas ranged from 
pure epithelioid cells extending radially from a wavy 
homogeneous eosinophilic central material in a pali- 
saded configuration to relatively loose granulomas 
composed of the same centrally located homoge- 
neous eosinophilic material surrounded by neutro- 
phils, macrophages, lymphocytes, plasma cells, 
eosinophils, and occasional foreign body and 
HISTOPATHOLOGIC FINDINGS 
Both biopsy speicmens were fixed in 10% buffered 
formalin for 24 hours and then routinely processed 
for hematoxylin and eosin staining (H&E). Periodic 
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FIGURE 3. A granuloma within dermis is partially sur- 
rounded by lymphocytes. 
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FIGURE 4. Giant cells are particularly prominent in this 
granuloma. 
Langhans' giant cells (Figs. 4 and 5). One granuloma 
in the deep dermis from Case 2 had a purulent center. 
Diffuse lymphoplasmocytic infiltrates were scattered 
throughout the dermis among the granulomas. Focal 
dense collagenous dermal scar was also present adja- 
cent to the granulomas; no polarizable material was 
noted in any of the granulomas. The homogeneous 
material in the center of the granulomas did not stain 
with PAS or alcian blue stains at either pH. With 
Movat's stain, considerable loss of elastic tissue was 
noted in the granulomatous areas. It is assumed that 
the homogeneous material within the center of some 
of the granulomas was Zyderm Collagen Implant 
(Fig. 5). 
In conclusion, we present two patients who devel- 
9 oped adverse local reactions to ZCI in spite of nega- 
tive reactions to intradermal skin test at 48 hours and 
at 1 month. A delayed hypersensitivity-mediated re- 
action to ZCI is suggested by the clinical course and 
the histologic finding of foreign-body-type granulo- 
mas within the dermis. The presence of urticaria clini- 
cally, elevated anti-Zyderm antibody titers serologi- 
cally, and plasma cells histologically suggest that 
humoral immunity is also actively involved in these 
reactions. Although these reactions were self-limited 
and local, continued monitoring of adverse reactions 
to ZCI is essential to evaluate its ultimate safety in the 
treatment of dermal defects. 
COMMENTS 
More than 10,000 patients have been treated with 
ZCI since the institution of clinical trials in 1976 and 
Federal Drug Administration approval for use as a 
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FIGURE 5. A dermal deposit of eosinophilic homogeneous 
material, presumably Zyderm, shows peripheral rimming 
and permeation by phagocytes which imparts a convoluted 
appearance to the deposit. 
medical device in August 1981. I We now have treated 
more than 200 patients with ZCI. 
Reported adverse reactions to ZCI have been rare. 
Data on file with the Collagen Corporation revealed a 
positive skin test, described as localized swelling, in- 
duration, erythema, pruritus, tenderness, or pain oc- 
curring in about 3% of 9,427 patients.' The reaction 
usually lasts from 3 days to 3 months. Systemic 
symptoms of generalized rash, arthralgias, myalgias, 
generalized pruritus, and mild edema at the injection 
site have also been reported after skin test implanta- 
tion. Adverse treatment reactions to injected ZCI in- 
clude bruising at the injection site and injection into 
small facial arteries. Other uncommon adverse re- 
sponses at treatment sites include infection (viral and 
bacterial) and transient swelling following alcohol in- 
gestion, sinusitis, or exposure to heat andlor sun- 
light. These reactions have been reported's2 in 33 of 
9,427 patients (0.4%). 
The histopathology of the granulomatous inflam- 
mation at the biopsy site suggests a spectrum ranging 
from foreign-body granulomas to allergic or hyper- 
sensitivity granulomas. Granulomas composed pri- 
marily of epithelioid cells that palisade around the 
central eosinophilic globular mass (Fig. 5) are typical 
of foreign-body granulomas in which the inciting for- 
eign substance is characterized by low solubility and 
low t o x i ~ i t y . ~ , ~  We assume that the central core of 
these granulomas is composed primarily of the ZCI 
but cannot prove this by light microscopic study. We 
are presently attempting to develop an immuno- 
peroxidase anti-Zyderm antibody conjugate in order 
to identify definitively the ZCI in tissue. Other 
present granulomas contain large numbers of the 
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lymphocytes and plasma cells. These are suggestive 
of hypersensitivity granu1omas.l The time course of 
the patient’s clinical reaction is certainly consistent 
with the delaved hypersensitivity reaction. Blast 
transformation of the patient’s lymphocytes in the 
presence of ZCI should be assayed to substantiate 
this supposition. The presence of numerous plasma 
cells within and adjacent to the granulomas may cor- 
relate with the presence of elevated titers of anti-Zy- 
derm antibody in the patient’s serum. The wheal and 
periorbital edema reactions at the injection site may 
also correlate with the presence of serum anti-Zy- 
derm antibodies since these usually indicate an im- 
mediate hypersensitivity reaction mediated by a hu- 
moral factor. 
Our patients have experienced only local reactions 
to ZCI. There is no evidence by history or routine 
serologic data (antinuclear antibody, erythrocyte 
sedimentation rate) to suggest systemic involvement. 
There is no clinical or laboratory evidence of any un- 
derlying immunologic abnormality in these patients 
although they have not been evaluated extensively. 
However, both patients’ serum exhibited anti-Zy- 
derm antibodies when compared to normal controls. 
The significance of this finding is unknown, The nat- 
ural course of the reaction seems to be remission over 
a period of months without development of systemic 
symptoms. 
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